Post-transplant monitoring of NK cell counts as a simple approach to predict the occurrence of opportunistic infection in liver transplant recipients

Transplant Infectious Disease

Volumn 18, Issue 4, 2016, Pages 552-565

  Fernandez Ruiz M ^a   Silva, J T ^a   Lopez Medrano F ^a   Allende, L M ^a   San Juan, R ^a   Cambra, F ^a   Justo, I ^a   Paz Artal, E ^a   Jimenez C ^a   Aguado, J M ^a  

^a Universidad Complutense   (Spain)

Author keywords

CMV disease; liver transplantation; NK cells; opportunistic infection; peripheral blood lymphocyte subpopulation

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CD16 ANTIGEN; CD56 ANTIGEN; CEFTAZIDIME; COTRIMOXAZOLE; CYCLOSPORIN; EVEROLIMUS; FLUCONAZOLE; GANCICLOVIR; MAMMALIAN TARGET OF RAPAMYCIN; MYCOPHENOLATE MOFETIL; PREDNISONE; STEROID; TACROLIMUS; TEICOPLANIN; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACCURACY; ACUTE GRAFT REJECTION; ADULT; ARTICLE; BIOLOGICAL MONITORING; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SUBPOPULATION; CEREBRAL PHAEOHYPHOMYCOSIS; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DISEASE SURVEILLANCE; ESOPHAGUS CANDIDIASIS; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; LIVER TRANSPLANTATION; LUNG ASPERGILLOSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MUCORMYCOSIS; NATURAL KILLER CELL; OPPORTUNISTIC INFECTION; PERIPHERAL LYMPHOCYTE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PULMONARY CRYPTOCOCCOSIS; RISK FACTOR;

EID: 84981163281     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12564     Document Type: Article

References (45)

1. Zarrinpar A, Busuttil RW. Liver transplantation: past, present and future. Nat Rev Gastroenterol Hepatol 2013; 10: 434–440.
2. Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012; 57: 675–688.
3. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010; 10: 1420–1427.
4. Kalil AC, Mindru C, Botha JF, et al. Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis. Liver Transpl 2012; 18: 1440–1447.
5. Kiel PJ, Dickmeyer N, Schwartz JE. Trimethoprim-sulfamethoxazole-induced rhabdomyolysis in an allogeneic stem cell transplant patient. Transpl Infect Dis 2010; 12: 451–454.
6. Koc M, Bihorac A, Ozener CI, Kantarci G, Akoglu E. Severe hyperkalemia in two renal transplant recipients treated with standard dose of trimethoprim-sulfamethoxazole. Am J Kidney Dis 2000; 36: E18.
7. Fernández-Ruiz M, Kumar D, Humar A. Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation. Clin Transl Immunology 2014; 3: e12.
8. Fernández-Ruiz M, López-Medrano F, Allende LM, et al. Kinetics of peripheral blood lymphocyte subpopulations predicts the occurrence of opportunistic infection after kidney transplantation. Transpl Int 2014; 27: 674–685.
9. Calarota SA, Zelini P, De Silvestri A, et al. Kinetics of T-lymphocyte subsets and posttransplant opportunistic infections in heart and kidney transplant recipients. Transplantation 2012; 93: 112–119.
10. Brunot V, Pernin V, Chartier C, et al. An epidemic of Pneumocystis jiroveci pneumonia in a renal transplantation center: role of T-cell lymphopenia. Transplant Proc 2012; 44: 2818–2820.
11. Sarmiento E, Navarro J, Fernández-Yanez J, Palomo J, Muñoz P, Carbone J. Evaluation of an immunological score to assess the risk of severe infection in heart recipients. Transpl Infect Dis 2014; 16: 802–812.
12. Romo EM, Muñoz-Robles JA, Castillo-Rama M, et al. Peripheral blood lymphocyte populations in end-stage liver diseases. J Clin Gastroenterol 2007; 41: 713–721.
13. + T cell counts in HIV-seronegative patients. Clin Infect Dis 2007; 44: 431–437.
14. Carbone J, Micheloud D, Salcedo M, et al. Humoral and cellular immune monitoring might be useful to identify liver transplant recipients at risk for development of infection. Transpl Infect Dis 2008; 10: 396–402.
15. Fernández-Ruiz M, López-Medrano F, Romo EM, et al. Pretransplant lymphocyte count predicts the incidence of infection during the first two years after liver transplantation. Liver Transpl 2009; 15: 1209–1216.
16. Nierenberg NE, Poutsiaka DD, Chow JK, et al. Pretransplant lymphopenia is a novel prognostic factor in cytomegalovirus and noncytomegalovirus invasive infections after liver transplantation. Liver Transpl 2014; 20: 1497–1507.
17. Fishman JA, Issa NC. Infection in organ transplantation: risk factors and evolving patterns of infection. Infect Dis Clin North Am 2010; 24: 273–283.
18. Ruiz P, Borowitz MJ, Tilahun H, et al. BD Biosciences Application Note. Productivity and efficiency of 6-color BD Multitest and BD Trucount technologies for enumeration of lymphocyte subsets, 2007. Available at: http://www.bd.com/resource.aspx?IDX=17742 (last accessed July 2, 2015).
19. Garrido RS, Aguado JM, Díaz-Pedroche C, et al. A review of critical periods for opportunistic infection in the new transplantation era. Transplantation 2006; 82: 1457–1462.
20. Aguado JM, Torre-Cisneros J, Fortún J, et al. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009; 48: 1276–1284.
21. Humar A, Michaels M; AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262–274.
22. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813–1821.
23. Jiménez C, Manrique A, Marqués E, et al. Incidence and risk factors for the development of lung tumors after liver transplantation. Transpl Int 2007; 20: 57–63.
24. Alegre C, Jiménez C, Manrique A, et al. Everolimus monotherapy or combined therapy in liver transplantation: indications and results. Transplant Proc 2013; 45: 1971–1974.
25. + T-cell determinations with CD45 gating for persons infected with human immunodeficiency virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003; 52: 1–13.
26. Nagai S, Yoshida A, Kohno K, et al. Peritransplant absolute lymphocyte count as a predictive factor for advanced recurrence of hepatitis C after liver transplantation. Hepatology 2014; 59: 35–45.
27. Nagai S, Abouljoud MS, Kazimi M, Brown KA, Moonka D, Yoshida A. Peritransplant lymphopenia is a novel prognostic factor in recurrence of hepatocellular carcinoma after liver transplantation. Transplantation 2014; 97: 694–701.
28. Abbas AK, Lichtman AH, Pillai S. Natural killer cells. In: Abbas AK, Lichtman AH, eds. Cellular and Molecular Immunology. Philadelphia, PA: Elsevier, 2012: 68–72.
29. Schmidt-Hieber M, Schwarck S, Stroux A, et al. Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion. Int J Hematol 2010; 91: 877–885.
30. Kheav VD, Busson M, Scieux C, et al. Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. Haematologica 2014; 99: 1860–1867.
31. Orange JS. Natural killer cell deficiency. J Allergy Clin Immunol 2013; 132: 515–525; quiz 526.
32. Jiao L, Gao X, Joyee AG, et al. NK cells promote type 1 T cell immunity through modulating the function of dendritic cells during intracellular bacterial infection. J Immunol 2011; 187: 401–411.
33. Esin S, Batoni G. Natural killer cells: a coherent model for their functional role in Mycobacterium tuberculosis infection. J Innate Immun 2015; 7: 11–24.
34. Shegarfi H, Sydnes K, Lovik M, Inngjerdingen M, Rolstad B, Naper C. The role of natural killer cells in resistance to the intracellular bacterium Listeria monocytogenes in rats. Scand J Immunol 2009; 70: 238–244.
35. Bouzani M, Ok M, McCormick A, et al. Human NK cells display important antifungal activity against Aspergillus fumigatus, which is directly mediated by IFN-gamma release. J Immunol 2011; 187: 1369–1376.
36. Fernández-Ruiz M, López-Medrano F, Varela-Peña P, et al. Monitoring of immunoglobulin levels identifies kidney transplant recipients at high risk of infection. Am J Transplant 2012; 12: 2763–2773.
37. Fernández-Ruiz M, López-Medrano F, Varela-Peña P, et al. Hypocomplementemia in kidney transplant recipients: impact on the risk of infectious complications. Am J Transplant 2013; 13: 685–694.
38. Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96: 333–360.
39. Mumtaz K, Faisal N, Husain S, Morillo A, Renner EL, Shah PS. Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis. Am J Transplant 2015; 15: 472–481.
40. Razonable RR, Hayden RT. Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation. Clin Microbiol Rev 2013; 26: 703–727.
41. Centers for Disease Control (CDC). Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. MMWR Morb Mortal Wkly Rep 1987; 36 (Suppl 1): 1S–15S.
42. bright natural killer (NK) cells: an important NK cell subset. Immunology 2009; 126: 458–465.
43. Guma M, Angulo A, Lopez-Botet M. NK cell receptors involved in the response to human cytomegalovirus infection. Curr Top Microbiol Immunol 2006; 298: 207–223.
44. Hadaya K, de Rham C, Bandelier C, et al. Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation. Am J Transplant 2008; 8: 2674–2683.
45. Egli A, Humar A, Kumar D. State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis 2012; 55: 1678–1689.